O
KDNY

OppenheimerFunds’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

OppenheimerFunds’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-163,183
Closed -$8.69M – 1883
2017
Q3 		$8.69M Sell
163,183
-54
-0% -$3.21K 0.01% 760
2017
Q2 		$9.3M Buy
+163,237
New +$8.19M 0.01% 750

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OppenheimerFunds's KDNY Position: Q4 2017 in Review

OppenheimerFunds sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2017, closing a stake of 163,183 shares — an estimated $8.69M sold.

OppenheimerFunds first reported a position in KDNY in Q2 2017 and held it in 2 quarters. The position peaked at $9.3M in Q2 2017. 94 funds tracked by Wall St. Rank hold KDNY as of Q4 2017.

  • OppenheimerFunds reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • OppenheimerFunds sold 163,183 Chinook Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $8.69M.
  • OppenheimerFunds first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • OppenheimerFunds's Chinook Therapeutics, Inc. Common Stock position peaked at $9.3M in Q2 2017.
  • 94 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2017.

Based on OppenheimerFunds's 13F filing for Q4 2017, filed 12 Feb 2018.